| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/30/2005 | WO2004093566A3 Functional animal muscle protein concentrate composition and process |
| 06/30/2005 | WO2004092210A3 Molecules having immunomodulatory activity |
| 06/30/2005 | WO2004078217A9 Bone calcification promoter |
| 06/30/2005 | WO2004058178A3 Uses of mammalian cytokine; related reagents |
| 06/30/2005 | WO2004035611A3 Peptides binding the phosphatase 2a protein and polynucleotides encoding same |
| 06/30/2005 | WO2004016643A3 Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines |
| 06/30/2005 | WO2004003172A3 Esm-1 gene differentially expressed in angiogenesis, antagonists thereof, and methods of using the same |
| 06/30/2005 | WO2004002424A8 Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
| 06/30/2005 | WO2004001381A3 Novel raag10 cell surface target and a family of antibodies recognizing that target |
| 06/30/2005 | WO2003106479A3 Pokeweed antiviral protein polypeptides with antiviral activity |
| 06/30/2005 | WO2003097807A3 Cancer-linked gene as target for chemotherapy |
| 06/30/2005 | WO2003064629A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 06/30/2005 | WO2003018611A3 Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer |
| 06/30/2005 | WO2002091999A3 Treatment for wounds |
| 06/30/2005 | US20050144663 Producing transgenic animals for obtaining useful proteins; combining genome from activated donor cell with activated, enucleated oocyte to form nuclear transfer embryo for impregnation |
| 06/30/2005 | US20050143817 Medical implants and anti-scarring agents |
| 06/30/2005 | US20050143802 Implantable system with drug-eluting cells for on-demand local drug delivery |
| 06/30/2005 | US20050143569 Polynucleotides, host cell expression systems, the encoded proteins, polypeptides and peptides |
| 06/30/2005 | US20050143567 Novel gonadotropin-releasing hormone, precursor peptides thereof and genes encoding the same |
| 06/30/2005 | US20050143562 Administering bone polypeptide-1 expressed by a nucleic acid for treating a bone disorder or osteoporosis of a patient |
| 06/30/2005 | US20050143560 Polypeptide analgesics from snail venom; analogous to the naturally available peptides, and which preferably include two disulfide bonds |
| 06/30/2005 | US20050143559 Tryparedoxin, expression plasmid, process of preparation, method of use, test kit and pharmaceutical composition |
| 06/30/2005 | US20050143472 Novel treatment for pathologies associated with oxidative damage |
| 06/30/2005 | US20050143463 endothelial cell proliferation; alkyl-substituted fatty acid with immunosuppressants as cyclosporin A, rapamycin or FK506; angiofibroma, neovascularisation, arteriovenous malformations, rheumatoid arthritis, lupus, connective tissue disorders, Osler-Weber syndrome, atherosclerotic plaques, psoriasis |
| 06/30/2005 | US20050143436 N-acylamino with fused nitrogen heterocyclic ring compound; capase enzyme inhibitors; antiinflammatory agents; oral bioavailability; autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases |
| 06/30/2005 | US20050143424 antidiabetic mixture contains an inhibitor of renal glucose reabsorption and a hypoglycemic agent; controlling blood glucose level; tolbutamide, chlorpropamide, glibenclamide, glipizide, glimepiride, and gliclazide; metformin, phenformin and buformin; repaglinide, nateglinide and mitiglinide |
| 06/30/2005 | US20050143411 Administering a macrolide such as FK-506 to treat airflow obstruction e.g. induced by cigarette smoke, chronic bronchitis, emphysema or chronic obstructive pulmonary disease |
| 06/30/2005 | US20050143391 Heterocyclic amides with alpha-4 integrin antagonist activity |
| 06/30/2005 | US20050143370 Therapeutic compounds |
| 06/30/2005 | US20050143357 Vitamin d upregulated protein 1 (vdup-) methods and uses thereof |
| 06/30/2005 | US20050143336 Prevent or reduce inflammation secondary to administration of a lipid-nucleic acid complex in a subject by co-administering a non-steroidal anti-inflammatory agent, a salicylate, an anti-rheumatic agent, an antihistamine, or an immunosuppressive agent with the lipid-nucleic acid complex |
| 06/30/2005 | US20050143335 Oligonucleotides, targeted to nucleic acids encoding Survivin; cancer |
| 06/30/2005 | US20050143333 RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA) |
| 06/30/2005 | US20050143331 Antisense phosphorothioate oligonucleotide inhibitor |
| 06/30/2005 | US20050143320 Protease inhibitors |
| 06/30/2005 | US20050143319 Peptide like compounds for treating coronavirus or hepatitis C virus; severe acute respiratory distress syndrome |
| 06/30/2005 | US20050143318 ((1R)-2-indol-3-yl-1-{N-[1-(2-oxo-1-phenyl-2-pyrrolidinylethyl)imidazol-4-yl]carbamoyl)ethyl)-2-[(tert-butoxy)carbonylamino]-2-methylpropanamide; combinded with bone-antiresorptive agent selected from selective estrogen receptor modulators, bisphosphonates, calcitonin, and PTH; carrieres, excipients |
| 06/30/2005 | US20050143317 Compounds and methods for treatment of thrombosis |
| 06/30/2005 | US20050143316 Hepatitis C virus inhibitors |
| 06/30/2005 | US20050143314 Compositions and methods to treat recurrent medical conditions |
| 06/30/2005 | US20050143313 Novel peptide, method of production thereof, and pharmaceutical composition containing the same |
| 06/30/2005 | US20050143312 Compositions and methods for promoting myocardial and peripheral angiogenesis |
| 06/30/2005 | US20050143310 Novel remedies for neurodegenerative disease |
| 06/30/2005 | US20050143309 Alkyl peptide amides and applications |
| 06/30/2005 | US20050143308 Survivin, a protein that inhibits cellular apoptosis, and its modulation |
| 06/30/2005 | US20050143307 Biological activity that prevents the binding of formyl methionine-leucine-phenylalanine (fMLP) and/or C5a protein to granulocytes; acute and chronic inflammation reactions and HIV infection |
| 06/30/2005 | US20050143306 Antigenic peptide fragments of growth differentiation factor 8, and related immunogens, vaccines; Immunization; drug screening |
| 06/30/2005 | US20050143305 sustained relese of saratin polypeptide to prevent platelet adhesion after vascular injury; thrombosis and restenosis inhibitor |
| 06/30/2005 | US20050143304 Osteogenic protein/bone morphogenetic proteins of eukaryotic origin |
| 06/30/2005 | US20050143303 Intranasal administration of glucose-regulating peptides |
| 06/30/2005 | US20050143302 Inhibiting NF-kappa B-dependent target gene expression in a cell; fusions of a NEMO binding domain and a membrane translocation domain (third helix of antennapedia homeodomain or the HIV-1 Tat protein) |
| 06/30/2005 | US20050143301 Gycosylated at one or more sites. an immunoglobulin fusion.; treating scleroderma; polypeptides or mutein |
| 06/30/2005 | US20050143300 Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same |
| 06/30/2005 | US20050143299 Use of relaxin as adjuvant in the differentiation of stem cells for the reconstruction of tissues |
| 06/30/2005 | US20050143298 Treating congestive heart failure by delivering a recombinant fibroblastic growth factor-2 or an angiogenically active fragment or an angiogenically active mutein by intravenous or intracoronary administration; benefit may last for up to six months |
| 06/30/2005 | US20050143297 Injection of multimerized forms of ligands of TNF family: FAs-ligand, CD40L, TRAIL and APRIL, into appropriate cavities of the body as anticell proliferative agent |
| 06/30/2005 | US20050143296 Extraction and utilization of cell growth-promoting peptides from silk protein |
| 06/30/2005 | US20050143295 Identification of genes found in particular brain regions of rats that are modulated by behavior associated with cocaine addiction and extinction training, GABA-B receptor subunit gb2, myelin-associated basic protein, calcitonin receptor, Bos taurus-like neuronal axonal protein, FRA-2, |
| 06/30/2005 | US20050143294 Neurotrophic factor-3 (NT-3), brain derived neurotrophic factor (BDNF), macrophage growth and differentiation factor (MGDF) and keratinocyte growth factor (KGF); lower isoelectric points; pharmacokinetics; treatment of peripheral neuropathies; bioavailability |
| 06/30/2005 | US20050143293 Peptides for enhancing resistance to microbial infections |
| 06/30/2005 | US20050143292 Glycopegylated erythropoietin |
| 06/30/2005 | US20050143291 Contacting a glucose regulated protein (GRP) with an agent( versipelostatin, deoxyadenosine 5.'triphosphate) that regulates the interaction of the GRP with a cytosolic component that mediates apoptosis |
| 06/30/2005 | US20050143289 Botulinum toxin pharmaceutical composition |
| 06/30/2005 | US20050143288 Use of lipid conjugates in the treatment of diseases |
| 06/30/2005 | US20050143285 Fluorescence based screening assays are provided that allow for the for identification of agents that selectively bind to a ligand-gated ion channels (LGIC); fluorescence resonance energy transfer (FRET) |
| 06/30/2005 | US20050143283 with a chelating agent; improves the solution stability; lyophilized; antithrombotic agent |
| 06/30/2005 | US20050142657 Expression vector for the production of annexin v |
| 06/30/2005 | US20050142642 Fc fusion proteins of human erythropoietin with increased biological activities |
| 06/30/2005 | US20050142641 antigens having altered antigenic profiles, uses in immunotherapy such as allergy vaccination and/or desensitization |
| 06/30/2005 | US20050142640 MUC-1 derived peptides |
| 06/30/2005 | US20050142639 Nucleotide sequence with vectors and administering apolipoproteins with data documents for binding lipids and cubulin for treatment of cardiovascular disorders |
| 06/30/2005 | US20050142635 chimeric antibodies comprising variable domain peptides, DNA codes for the antibodies, expression vectors, host cells and a process of culturing the host cells to produce the monoclonal antibodies, used for immunotherapy; nonimmunogenic |
| 06/30/2005 | US20050142625 monoclonal antibodies or antigen-binding fragments having specific binding affinity to an epitope of protein kinases polypeptides, used for the diagnosis and treatment of various kinase-related diseases in humans |
| 06/30/2005 | US20050142620 Compositions and methods for the therapy and diagnosis of lung cancer |
| 06/30/2005 | US20050142617 gene related to bone density; possible use in the drug screening, treatment, and diagnosis of bone disorders such as osteoporosis |
| 06/30/2005 | US20050142615 Immunization of dairy cattle with chimeric GapC protein against Streptococcus infection |
| 06/30/2005 | US20050142612 Inhibitors of amyloid precursor protein processing |
| 06/30/2005 | US20050142604 Methods and compositions to treat cardiovascular disease using 1419, 58765 and 2210 |
| 06/30/2005 | US20050142600 Protein modification and maintenance molecules |
| 06/30/2005 | US20050142578 Introducing library of siNA constructs into a biological system; determining nucleotide sequence of a siNA construct in which a process has been modulated; cellular proliferation, differentiation, morphology, angiogenesis, migration, viral multiplication; gene expression and engineering; transcription |
| 06/30/2005 | US20050142566 Sperm-specific cation channel, catSper2, and uses therefor |
| 06/30/2005 | US20050142557 Polynucleotides and polypeptides of Anaplasma phagocytophilum and methods of using the same |
| 06/30/2005 | US20050142552 Susceptibility locus for schizophrenia |
| 06/30/2005 | US20050142546 Assays for identifying modulators of rhomboid polypeptides |
| 06/30/2005 | US20050142535 Ogligonucleotides comprising alternating segments and uses thereof |
| 06/30/2005 | US20050142209 Comprising bovine bones, cuttlefish bones, red algae and an organic acid (eg acetic acid, lactic acid or citric acid); pills; health food |
| 06/30/2005 | US20050142206 Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation |
| 06/30/2005 | US20050142201 Human growth hormone (hGH); liquid-solid phase separation; solid form |
| 06/30/2005 | US20050142183 Expressing by means of a eukaryotic or prokaryotic vector, in which a nucleic acid coding for the mistletoe lectin polypeptide according to the usual genetic code or the fragment thereof is cloned in a suitable heterologous eukaryotic or prokaryotic host |
| 06/30/2005 | US20050142180 Comprises doses of Apolipoprotein A-I Milano:phospholipid complex to reduce and stabilize atherosclerotic plaque; for treating ischemic reperfusion |
| 06/30/2005 | US20050142166 Fermenting food material comprising animal milk proteins (casein) or vegetable proteins with proteolytic lactic acid bacterium and lytic lactic acid bacterium (lactobacillus, lactococcus) |
| 06/30/2005 | US20050142163 Treatment for an orthopedic condition using agents such as silk or bleomycin |
| 06/30/2005 | US20050142162 Soft tissue implants and anti-scarring agents |
| 06/30/2005 | US20050142150 Botulinum toxin formulations |
| 06/30/2005 | US20050142149 Virulence genes and proteins, and their use |
| 06/30/2005 | US20050142146 Vaccine; against Chlamydia pneumonia; therapy, prevention of infections, |
| 06/30/2005 | US20050142144 Epitope sequences |
| 06/30/2005 | US20050142142 recombinant T cell receptor ligand (RTL) for use treating autoimmune diseases |
| 06/30/2005 | US20050142140 Immunoadhesin comprising a glycoprotein VI domain |
| 06/30/2005 | US20050142138 Endothelial cell expression patterns |